Revolutionary CAR-T Cell Therapies: A New Era in Cancer Treatment
Promega's contribution to the development and verification of genetically modified CAR-T cells is driving innovation in cancer immunotherapy.
Genetically modified T cell therapies, particularly CAR-T cells, represent a groundbreaking advancement in the treatment of various cancers such as acute lymphoblastic leukemia, certain lymphomas, and multiple myeloma. CAR-T cells are created by modifying a patient’s immune cells with chimeric antigen receptors (CAR) that enable the immune system to identify and destroy tumor cells.
The process of generating CAR-T cells involves five key steps: isolating T cells from the patient’s blood, activating them to accept a viral vector containing the CAR genetic construct, expanding the cells in culture, and finally administering them intravenously to the patient. Each CAR-T dose is unique and presents challenges related to quality control, ensuring safety, stability, and potency at every stage.
An essential tool in verifying the identity of these cells is the Short Tandem Repeat (STR) analysis, a genetic identification technique. STR profiling helps ensure that the cells remain consistent throughout the manufacturing process by comparing genetic markers from the patient to the modified cells. This technique also proves valuable in allogeneic T cell therapies, which use cells from healthy donors, offering potential for large-scale treatments.
Promega provides comprehensive instrumentation and reagents to support the entire CAR-T cell workflow, from sample extraction to capillary electrophoresis analysis. Additionally, Promega’s luminescent technology optimizes real-time, quantitative measurements in living cell environments, supporting innovative therapeutic approaches like targeted protein degradation.